{"id":"aigc-v0-889385df-cf72-5200-8cd9-d4d8f7be21f5","title":"Major Cancer Drug Recall: Cipla USA Pulls Over 400 Cartons of Nilotinib Capsules in the US","description":"Discover the details of Cipla USA's voluntary recall of Nilotinib Capsules, affecting over 400 cartons due to quality specifications. This report explains the nature of the recall and its implications.","timestamp":1773052113,"category":"food_and_health","headline":"Major Cancer Drug Recall: Cipla USA Pulls Over 400 Cartons of Nilotinib Capsules in the US","modifiedHeadline":"Cipla USA Recalls Cancer Drug Nilotinib","subCategories":["scid_cda1a7ee"],"subcategoriesName":["Diseases"],"region":"IN","bundleMetaData":{"bundleId":"7b48871c-c993-4956-b43d-6f46f8e1b036","bundleTitle":"Today In India","cardData":null},"iabCategoryId":"320","fcSummary":"cipla usa initiated a voluntary recall of over 400 cartons of nilotinib capsules (150mg & 200mg) due to failed specifications, as reported by the usfda. it's a class iii recall, not expected to cause adverse health effects. nilotinib treats certain cancers by inhibiting abnormal protein signaling. india's pharmaceutical industry, with its numerous usfda-compliant facilities, significantly supplies medications to the u.s.","summary":"Cipla USA recalls over 400 cartons of Nilotinib capsules due to quality issues. A Class III recall, impacting cancer treatment.","ctaUrl":"https://trends.glance.com/newz/international/IN/en/feedpost-specials/aigc-v0-889385df-cf72-5200-8cd9-d4d8f7be21f5?byte=true","sourceUrl":"https://trends.glance.com/newz/international/IN/en/feedpost-specials/aigc-v0-889385df-cf72-5200-8cd9-d4d8f7be21f5?byte=true","bannerImage":"https://g-mob.glance-cdn.com/public/fc/image/ac0Z91yuXJD0.webp","content":"

\n A significant recall of a vital cancer drug, Nilotinib Capsules, has been initiated by Cipla USA in the United States. Learn about the reasons behind this voluntary action and what it means.\n

Recall Initiated

Cipla USA, Inc. has recently initiated a voluntary recall encompassing more than 400 cartons of Nilotinib Capsules, available in both 150 mg and 200 mg strengths.

\n \n

This action, documented in the US Food and Drug Administration's (USFDA) latest Enforcement Report, stems from the identified issue of \"failed tablet/capsule specifications.\" The recall specifically involves lot numbers 271 and 164 cartons, and it was formally commenced on February 18th of this year. The USFDA categorizes this as a Class III recall, a designation indicating that while the product has a violation, its use or exposure is not anticipated to cause adverse health effects. This proactive measure highlights the company's commitment to maintaining product integrity and patient safety in the pharmaceutical market.

\n\n

Understanding Nilotinib

Nilotinib is a crucial medication employed in the treatment of certain types of cancer. Its mechanism of action involves inhibiting the function of an abnormal protein that typically signals cancer cells to proliferate. By blocking this signaling pathway, Nilotinib effectively helps to halt or slow down the progression and spread of cancerous cells within the body. This targeted approach makes it a valuable therapeutic agent in oncology. The recall of this specific drug underscores the stringent quality control measures in place within the pharmaceutical industry, particularly for medications impacting serious health conditions.

\n\n

India's Pharmaceutical Strength

The pharmaceutical industry in India plays a pivotal role in global drug supply chains, evidenced by the nation possessing the highest number of USFDA-compliant manufacturing facilities outside of the United States. Indian pharmaceutical companies are instrumental in meeting the medication needs of US residents, contributing a substantial portion of the drugs prescribed. In fact, data from 2022 indicates that approximately four out of every ten prescriptions filled in the US were supplied by Indian companies. This significant presence underscores the reliability and scale of India's pharmaceutical manufacturing capabilities and its importance to international healthcare access.

\n","readDurationInMinutes":"4","author":{"name":"Feedpost Specials","logo":"https://glance-mob.glance-cdn.com/public/bubble/jpeg/d7fdd6b5-4bee-4287-ab8a-8958c18b6f7c.jpeg"},"ism":false,"analyticsResponses":[],"pointerSummary":["Cipla USA recalled over 400 cartons of Nilotinib capsules due to specification failures.","The USFDA classified the recall as Class III, meaning no adverse health effects are expected.","India’s pharmaceutical firms supply ~40% of US prescriptions, highlighting its vital role."],"tags":["CiplaUSA","DrugRecall","NilotinibCapsules","CancerDrug","USFDA","Pharmaceuticals","ProductRecall","PatientSafety","ClassIIIRecall","IndiaPharma"],"redirectionEnabled":false,"consent":true}

Major Cancer Drug Recall: Cipla USA Pulls Over 400 Cartons of Nilotinib Capsules in the US

SUMMARY